Bridgetech Holdings International (San Diego), a company focused on maximizing the potential of emerging healthcare products and services in China and the U.S., has filed its Form 10-SB registration statement with the Securities and Exchange Commission (SEC).

This filing is required to move the company to reporting status under the Securities and Exchange Act of 1934, and is subject to the SEC's review and comment process. Once this registration statement is reviewed and becomes effective, the company will be eligible for quotation on the OTC Bulletin Board.

"We are eager to move onto the OTC Bulletin Board and to become a fully reporting entity," said Michael Chermak, president and CEO of Bridgetech. "This is another key component of our strategy and will put us in position to evaluate an eventual move up to a larger national exchange."

Bridgetech is leveraging its network of relationships in China and the U.S. to capitalize on the demand for Western healthcare in China. The company is bringing emerging drugs, devices and diagnostics to China, with an initial focus on oncology and women's health.

Bridgetech also is focused on the areas of nurse recruitment and training, medical imaging and non-invasive surgery, and RFID-based hospital asset management.

AABB joins Lab Tests Online

AABB (formerly known as the American Association of Blood Banks; Washington) is the newest partner to join the professional collaboration behind Lab Tests Online (www.labtestsonline.org), the award-winning patient education web site for laboratory testing information created by the American Association for Clinical Chemistry (also Washington).

AABB is the 17th professional laboratory organization to support the editorial development of the site.

Lab Tests Online provides patients and their caregivers with easy-to-understand information about specific diagnostic tests and related topics such as reference ranges, screening, and genetic testing.

Imaging Diagnostics contracts with M Squared

Imaging Diagnostic Systems (IDSI; Fort Lauderdale, Florida) said that M Squared Associates (Washington) has been selected by IDSI to audit and monitor the company's clinical trials.

M Squared Associates will provide both expertise in clinical study management as well as experience with the FDA, Imaging Diagnostics said. The company's senior staff includes past executive managers from both Fortune 500 and early-stage medical device companies, as well as past managers from the FDA Center for Devices and Radiological Health.